Singh O, Rao L V, Gaur A, Sharma N C, Alam A, Talwar G P
National Institute of Immunology, New Delhi, India.
Fertil Steril. 1989 Nov;52(5):739-44.
Data are presented on antibody titers generated in 88 women immunized with three formulations of antihuman chorionic gonadotropin (hCG) vaccine, namely, beta-hCG (formulation B); beta-hCG associated with alpha-subunit of ovine luteinizing hormone (LH) (formulation A) and beta-hCG + beta-ovine LH (formulation M), each linked to tetanus toxoid and cholera toxin chain B as carriers. Each formulation was tested at two dose levels (100 and 500 micrograms). All women without exception developed anti-hCG antibodies having hCG-binding capacity above 20 ng mL-1 (0.5 nM), a level considered to be the threshold for prevention of pregnancy. Formulations A and B gave relatively better immunogenic response in human subjects than M. In each case, the antibody response was reversible. The mean duration of response above 20 ng was 35 to 37 weeks for formulation A, 34 weeks for B, and 17 to 20 weeks for M. Antibodies induced by three formulations of the vaccine had high-affinity (Ka 10(9)-10(10)M-1) for binding with hCG. They were devoid of cross-reaction with human follicle-stimulating hormone and thyroid-stimulating hormone but, as expected, cross-reacted with human LH. Antibodies were competent to block the hCG induced ovarian hyperemia.
本文呈现了88名女性接种三种抗人绒毛膜促性腺激素（hCG）疫苗制剂后产生的抗体滴度数据，这三种制剂分别是：β-hCG（制剂B）；与羊促黄体生成素（LH）α亚基结合的β-hCG（制剂A）以及β-hCG + β-羊LH（制剂M），每种制剂均与破伤风类毒素和霍乱毒素B链作为载体相连。每种制剂在两个剂量水平（100微克和500微克）下进行了测试。所有女性无一例外均产生了hCG结合能力高于20 ng/mL（0.5 nM）的抗hCG抗体，该水平被认为是预防妊娠的阈值。制剂A和B在人体受试者中产生的免疫原性反应相对优于制剂M。在每种情况下，抗体反应都是可逆的。制剂A抗体反应高于20 ng的平均持续时间为35至37周，制剂B为34周，制剂M为17至20周。三种疫苗制剂诱导产生的抗体与hCG结合具有高亲和力（Ka 10⁹ - 10¹⁰M⁻¹）。它们与人促卵泡生成素和促甲状腺激素无交叉反应，但正如预期的那样，与人LH有交叉反应。这些抗体能够阻断hCG诱导的卵巢充血。
